Histogen Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Histogen's earnings have been declining at an average annual rate of -9.7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 99.5% per year.
Belangrijke informatie
-9.7%
Groei van de winst
31.3%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -99.5% |
| Rendement op eigen vermogen | -281.2% |
| Nettomarge | -65,142.1% |
| Laatste winstupdate | 30 Sep 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Histogen stock down 8% after Q2 loss, on track for six-day losing streak
Aug 12Histogen announces pricing of $5M private placement
Jul 12We're A Little Worried About Histogen's (NASDAQ:HSTO) Cash Burn Rate
Dec 02
Histogen jumps 11% after Intracoastal Capital reports 5.6% stake
Jun 16Histogen enters $6.5M at-the-market direct offering
Jun 07Histogen under pressure on pricing $14M upsized public offering
Dec 31Histogen files IND application for regenerative human matrix
Dec 17Histogen soars after HST-001 data in male pattern baldness
Dec 01Opbrengsten en kosten
Hoe Histogen geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -12 | 9 | 0 |
| 30 Jun 23 | 0 | -12 | 9 | 0 |
| 31 Mar 23 | 0 | -14 | 9 | 0 |
| 31 Dec 22 | 4 | -11 | 9 | 0 |
| 30 Sep 22 | 4 | -11 | 9 | 0 |
| 30 Jun 22 | 4 | -12 | 8 | 0 |
| 31 Mar 22 | 4 | -11 | 8 | 0 |
| 31 Dec 21 | 1 | -15 | 8 | 0 |
| 30 Sep 21 | 2 | -15 | 8 | 0 |
| 30 Jun 21 | 1 | -15 | 8 | 0 |
| 31 Mar 21 | 2 | -21 | 8 | 0 |
| 31 Dec 20 | 2 | -19 | 7 | 0 |
| 30 Sep 20 | 3 | -18 | 7 | 0 |
| 30 Jun 20 | 3 | -15 | 6 | 0 |
| 31 Mar 20 | 4 | -9 | 6 | 0 |
| 31 Dec 19 | 11 | -3 | 6 | 0 |
| 30 Sep 19 | 10 | -2 | 5 | 0 |
| 31 Dec 18 | 2 | -6 | 3 | 0 |
| 31 Dec 17 | 10 | 2 | 3 | 0 |
Kwaliteitswinsten: HSTO is currently unprofitable.
Groeiende winstmarge: HSTO is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if HSTO's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare HSTO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: HSTO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: HSTO has a negative Return on Equity (-281.18%), as it is currently unprofitable.